Form 4: Lifecore Biomedical Executive Thomas D. Salus Reports Acquisition of Shares and Derivative Securities
SEC Form 4 Filing
Thomas D. Salus, Chief Legal & Administration Officer of Lifecore Biomedical, reports acquiring common stock and performance-based restricted stock units.
Summary
- On April 14, 2025, Thomas D. Salus, Chief Legal & Administration Officer of Lifecore Biomedical, reported transactions involving the company's securities.
- Salus acquired 45,000 shares of common stock and an additional 170,000 shares, bringing his total direct ownership to 215,000 shares.
- He also acquired 370,000 performance-based restricted stock units, which convert into common stock upon achieving certain stock price milestones and expire on April 14, 2030.
- Additionally, Salus acquired incentive stock options (Right to Buy) for 210,000 shares of common stock at an exercise price of $6.17, exercisable between April 14, 2026 and April 14, 2032.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and stock options by an executive suggests confidence, but the performance-based vesting introduces uncertainty.
Positives
- The acquisition of shares and stock options by a company executive could be seen as a positive signal, indicating confidence in the company's future performance.
Future Outlook
The vesting of the performance-based restricted stock units is contingent upon Lifecore Biomedical achieving certain stock price milestones.
Industry Context
Insider transactions are routinely monitored as they can provide insights into a company's prospects, although they don't always indicate a definitive trend.
Stakeholder Impact
- Shareholders may view the executive's stock acquisition as a positive sign.
- The vesting of performance-based restricted stock units aligns executive compensation with company performance, potentially benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/14/2025 | Date of transaction for common stock acquisition and grant of performance-based restricted stock units and incentive stock options. |
| 04/14/2026 | Earliest date the incentive stock options become exercisable. |
| 04/14/2030 | Expiration date for the performance-based restricted stock units. |
| 04/14/2032 | Expiration date for the incentive stock options. |
| 04/16/2025 | Date of signature for the Form 4 filing. |
Keywords
Lifecore Biomedical, Thomas D. Salus, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Common Stock, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.